Erlotinib in non-small cell lung cancer treatment: current status and future development
C Gridelli, MA Bareschino, C Schettino, A Rossi… - The …, 2007 - academic.oup.com
C Gridelli, MA Bareschino, C Schettino, A Rossi, P Maione, F Ciardiello
The oncologist, 2007•academic.oup.comLearning Objectives After completing this course, the reader will be able to: Describe the
molecular mechanism of action of erlotinib. Define clinical and molecular predictors of
response to erlotinib. Describe the clinical trials performed with erlotinib in NSCLC and
underline future clinical development of this drug in the treatment of NSCLC. CME Access
and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.
TheOncologist. com
molecular mechanism of action of erlotinib. Define clinical and molecular predictors of
response to erlotinib. Describe the clinical trials performed with erlotinib in NSCLC and
underline future clinical development of this drug in the treatment of NSCLC. CME Access
and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.
TheOncologist. com
Learning Objectives
After completing this course, the reader will be able to:
- Describe the molecular mechanism of action of erlotinib.
- Define clinical and molecular predictors of response to erlotinib.
- Describe the clinical trials performed with erlotinib in NSCLC and underline future clinical development of this drug in the treatment of NSCLC.
CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Oxford University Press